List view / Grid view
Welcome to European Pharmaceutical Review’s Guide to Outsourcing. In this edition, Gil Roth, President of the Pharma & Biopharma Outsourcing Association (PBOA) reflects on the fortunes and challenges of the CDMO sector, highlighting their invaluable place in today’s drug development strategies, and Associates of Cape Cod and Charles River showcase…
David Vincent, Process Development Lead at eXmoor Pharma, details some of the critical steps that form the manufacturing strategy for providers of cell and gene therapies.
The global cell and gene therapy manufacturing services market is expected to grow at a CAGR of 12.4 percent in the next five years.
Market research suggests the Asia Pacific region could soon overtake Europe and North America in the active pharmaceutical ingredient (API) contract development and manufacturing organisation (CDMO) market.
Growth in the pharmaceutical contract manufacturing market to be driven by advanced technologies, the rising aging population and the increase in chronic disease cases, says report.
In a presentation, experts revealed that contract services gained significantly through pandemic contracts but cautioned that capacity shortages could continue.
Research shows the complexity and number of biologics is increasing, as is the frequency at which their active pharmaceutical ingredient (API) production is outsourced.
Research suggests the increasing R&D investment in and adoption of biologics will drive growth in the global biologics contract development and manufacturing organisation (CDMO) market.
A new report suggests the global biotechnology and pharmaceutical services outsourcing market will grow because of the pandemic and rising drug development costs and R&D investments.
Active pharmaceutical ingredients (APIs) are primary components in the manufacture of drugs, yet this global market experiences numerous challenges. Regulatory pressure, pricing arbitrages, a shift to digital manufacturing and patents for blockbuster drugs are chief among them, but the COVID-19 pandemic added a further hurdle as governments globally decided to…
Reports have found that the COVID-19 pandemic is providing new opportunities for contract and development manufacturing organisations (CDMOs).
A new analysis suggests that Europe and North America will capture more than 80 percent of the $9.3 billion market by 2030.